SynthesisJournal of the neurological sciences2021
Guillain Barré Syndrome and its variants as a manifestation of COVID-19: A systematic review of case reports and case series.
Synthesis in Journal of the neurological sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 95 citations in OpenAlex.
- A Comprehensive Systematic Review of CSF analysis that defines Neurological Manifestations of COVID-19.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2021Pooled it
- Population-Based Incidence of Guillain-Barré Syndrome During Mass Immunization With Viral Vaccines: A Pooled Analysis.Frontiers in immunologyPooled it
- Viral triggers of Guillain-Barré syndrome: implications for laboratory diagnostics.Biochemia medica · 2026Review
- Guillain-Barré syndrome and its variants during COVID-19 pandemic: a retrospective study in Iran.BMC neurology · 2026Article
- Guillain-Barré Syndrome (GBS) as a COVID-19 Complication: A Multicenter Study Conducted Throughout the 2-Year Pandemic.Advanced biomedical research · 2026Article
- Integrating case reports into systematic reviews: methodological strategies and challenges.Systematic reviews · 2025Article
- A propensity score matched retrospective study of psychological and behavioral therapy impact on muscle function recovery in Guillain Barré Syndrome.Scientific reports · 2025Article
- Analysis of diet-related stroke disease burden in China from 1990 to 2021 and projections for 2025-2044.Frontiers in nutrition · 2025Article
- Risk of neurologic or immune-mediated adverse events after COVID-19 diagnosis in the United States.PloS one · 2025Article
- Journey of Guillain Barre syndrome from the pre-pandemic era to the pandemic era: A 4-year retrospective study.Journal of family medicine and primary care · 2024Article
- The Impact of COVID-19 on the Guillain-Barré Syndrome Incidence.Biomedicines · 2024Review
- Controversies in COVID-19: Diagnostic Evaluation and Management in Neuro-COVID.Advances in experimental medicine and biology · 2024Review
- Guillain-Barré Syndrome Presenting as Symmetrical Proximal Muscle Weakness: An Atypical Presentation.Cureus · 2023Article
- Neurological Sequelae of COVID-19: A Biochemical Perspective.ACS omega · 2023Review
- Guillain-Barré Syndrome Associated with SARS-CoV-2 in Two Pediatric Patients.Sultan Qaboos University medical journal · 2023Article
- SARS-CoV-2 and the nervous system: current perspectives.Archives of virology · 2023Review
- Guillain-Barré syndrome associated with COVID-19: A systematic review.Brain, behavior, & immunity - health · 2023Review
- Guillain-Barré syndrome AMSAN variant in a 90-year-old woman after COVID-19: a case report.BMC geriatrics · 2023Article
- Neurologic Manifestations of Coronavirus Disease 2019 in Children: An Iranian Hospital-Based Study.Archives of Iranian medicine · 2023Article
- Acute motor-sensory axonal polyneuropathy variant of Guillain-Barré syndrome with a thalamic lesion and COVID-19: a case report and discussion on mechanism.Frontiers in neurology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 9 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe COVID-19 pandemic caused by SARS-COV-2 began in Wuhan, China in December 2019. Reports of COVID-19 with central (CNS) and peripheral nervous (PNS) system manifestations are emerging. In this systematic review, we compared and summarized the demographics, clinical features, Brighton criteria, immunological and laboratory findings with a focus on modified Erasmus GBS Outcome Score (mEGOS) in SARS-CoV-2 patients with GBS and its variants.
methodsBased on PRISMA guidelines, we searched three databases (PubMed, Scopus, and Google Scholar) for studies on COVID-19 and GBS between December 1, 2019 to July 15, 2020. For descriptive analysis, we studied two groups with: 1) acute inflammatory demyelinating polyradiculoneuropathy (AIDP) variant, and 2) Non-AIDP/Other variants. We compared mEGOS scores for patients in both groups along with other key clinical features.
resultsOf the 50 GBS cases identified from 37 studies, 33 (66%) had acute inflammatory demyelinating polyradiculopolyneuropathy (AIDP) while 17 (34%) were of other (non-AIDP) variants. There mEGOS scores did not differ between AIDP patients and AMAN/AMSAN patients. Majority of the AIDP (66.7%) and AMAN/AMSAN (57.2%) patients belonged to Brighton level 1 indicating maximum diagnostic certainty.
conclusionTo our knowledge, this is among the first reviews that includes GBS variants and the clinical prediction tool mEGOS for prognostication in COVID-19 patients. Further research is needed to assess whether IVIG is preferable over plasmapheresis in this population of GBS patients. It would also be crucial to follow these patients over time to identify the long-term disability as well as treatment outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.